{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T16:12:24Z","timestamp":1714579944431},"reference-count":38,"publisher":"Bentham Science Publishers Ltd.","issue":"1","license":[{"start":{"date-parts":[[2016,3,7]],"date-time":"2016-03-07T00:00:00Z","timestamp":1457308800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"content-domain":{"domain":["openophthalmologyjournal.com","benthamopen.com"],"crossmark-restriction":true},"short-container-title":["TOOPHTJ"],"published-print":{"date-parts":[[2016,3,7]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose: <\/jats:title>\n                    <jats:p>To prospectively assess the efficacy and safety of switching to bimatoprost monotherapy or brinzolamide and latanoprost combination therapy in patients who had been receiving latanoprost monotherapy.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                    <jats:title>Methods: <\/jats:title>\n                    <jats:p>A prospective, open-label study was conducted. Patients with primary open-angle glaucoma or ocular hypertension who had been receiving latanoprost monotherapy for three months or more were enrolled. Bimatoprost was substituted for latanoprost in one eye (BIM group), and brinzolamide was added to the latanoprost in the other eye (BRZ group) simultaneously. The patients underwent examinations at 6 weeks (visit 1) and 12 weeks (visit 2) after changing therapies. Subsequently, the treatments were returned to latanoprost monotherapy. The patients underwent another examination 6 weeks (visit 3) after the return to latanoprost. The parameters examined were intraocular pressure (IOP), conjunctival hyperemia, and corneal epithelial damage. <\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                    <jats:title>Results:  <\/jats:title>\n                    <jats:p>Twenty-six patients (13 men and 13 women) completed the protocol. Both groups showed a significant IOP reduction at visits 1 and 2 compared with the baseline, with a similar magnitude (BIM group: P = 0.016 at visit 1, P = 0.025 at visit 2, BRZ group: P = 0.0006 at visit 1, P = 0.028 at visit 2). The IOPs at the baseline and on visit 3 were similar in both groups (P = 0.7). The two groups showed no changes in either conjunctival hyperemia or corneal epithelial damage compared with the baseline.  <\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                    <jats:title>Conclusion: <\/jats:title>\n                    <jats:p>Bimatoprost monotherapy and brinzolamide adjunctive to latanoprost similarly reduced the IOP, with no additive adverse effects, compared with latanoprost monotherapy.               <\/jats:p>\n                <\/jats:sec>","DOI":"10.2174\/1874364101610010094","type":"journal-article","created":{"date-parts":[[2016,3,7]],"date-time":"2016-03-07T13:05:01Z","timestamp":1457355901000},"page":"94-102","update-policy":"http:\/\/dx.doi.org\/10.2174\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and Safety of Switching Latanoprost Monotherapy to Bimatoprost Monotherapy or Combination of Brinzolamide and Latanoprost"],"prefix":"10.2174","volume":"10","author":[{"given":"Mitsuhiro","family":"Imasawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joji","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumiko","family":"Kashiwagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Kashiwagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"refR1","first-page":"471","volume":"104","author":"Actis A.G.","year":"2013","unstructured":"Actis AG, Dall\u2019Orto L, Penna R, Brogliatti B, Rolle T. \n                    An internal medicine perspective review of risk factors for assessing and progression of primary open angle glaucoma. \n                    Minerva Med  \n                    2013; \n                    104\n                    (4)\n                    : 471-85.","journal-title":"Minerva Med."},{"key":"refR2","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1345\/aph.1A178","volume":"36","author":"Alexander C.L.","year":"2002","unstructured":"Alexander CL, Miller SJ, Abel SR. \n                    Prostaglandin analog treatment of glaucoma and ocular hypertension. \n                    Ann Pharmacother  \n                    2002; \n                    36\n                    (3)\n                    : 504-11.","journal-title":"Ann. Pharmacother."},{"key":"refR3","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1124\/pr.112.007088","volume":"65","author":"Woodward D.F.","year":"2013","unstructured":"Woodward DF, Wang JW, Poloso NJ. \n                    Recent progress in prostaglandin F2\u03b1 ethanolamide (prostamide F2\u03b1) research and therapeutics. \n                    Pharmacol Rev  \n                    2013; \n                    65\n                    (4)\n                    : 1135-47.","journal-title":"Pharmacol. Rev."},{"key":"refR4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2174\/1874364101004010007","volume":"4","author":"Kashiwagi K.","year":"2010","unstructured":"Kashiwagi K. \n                    Changes in trend of newly prescribed anti-glaucoma medications in recent nine years in a Japanese local community. \n                    Open Ophthalmol J  \n                    2010; \n                    4\n                    : 7-11.","journal-title":"Open Ophthalmol. J."},{"key":"refR5","doi-asserted-by":"publisher","first-page":"S337","DOI":"10.1016\/S0039-6257(01)00224-7","volume":"45","author":"Woodward D.F.","year":"2001","unstructured":"Woodward DF, Krauss AH, Chen J, et al. \n                    The pharmacology of bimatoprost (Lumigan). \n                    Surv Ophthalmol  \n                    2001; \n                    45\n                    (Suppl 4)\n                    : S337-45.","journal-title":"Surv. Ophthalmol."},{"key":"refR6","doi-asserted-by":"publisher","first-page":"663","DOI":"10.2147\/OPTH.S6337","volume":"3","author":"Smid S.D.","year":"2009","unstructured":"Smid SD. \n                    Role of prostaglandins and specific place in therapy of bimatoprost in the treatment of elevated intraocular pressure and ocular hypertension: A closer look at the agonist properties of bimatoprost and the prostamides. \n                    Clin Ophthalmol  \n                    2009; \n                    3\n                    : 663-70.","journal-title":"Clin. Ophthalmol."},{"key":"refR7","doi-asserted-by":"publisher","first-page":"S353","DOI":"10.1016\/S0039-6257(01)00212-0","volume":"45","author":"DuBiner H.","year":"2001","unstructured":"DuBiner H, Cooke D, Dirks M, Stewart WC, VanDenburgh AM, Felix C. \n                    Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost. \n                    Surv Ophthalmol  \n                    2001; \n                    45\n                    (Suppl 4)\n                    : S353-60.","journal-title":"Surv. Ophthalmol."},{"key":"refR8","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1016\/S0149-2918(01)80150-8","volume":"23","author":"DuBiner H.B.","year":"2001","unstructured":"DuBiner HB, Mroz M, Shapiro AM, Dirks MS. \n                    A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open-angle glaucoma or ocular hypertension: a three-month, multicenter, randomized, double-masked, parallel-group trial. \n                    Clin Ther  \n                    2001; \n                    23\n                    (12)\n                    : 1969-83.","journal-title":"Clin. Ther."},{"key":"refR9","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/BF02850259","volume":"20","author":"Noecker R.J.","year":"2003","unstructured":"Noecker RJ, Earl ML, Mundorf T, Peace J, Williams RD. \n                    Bimatoprost 0.03% versus travoprost 0.004% in black Americans with glaucoma or ocular hypertension. \n                    Adv Ther  \n                    2003; \n                    20\n                    (2)\n                    : 121-8.","journal-title":"Adv. Ther."},{"key":"refR10","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/BF02850159","volume":"23","author":"Dirks M.S.","year":"2006","unstructured":"Dirks MS, Noecker RJ, Earl M, Roh S, Silverstein SM, Williams RD. \n                    A 3-month clinical trial comparing the IOP-lowering efficacy of bimatoprost and latanoprost in patients with normal-tension glaucoma. \n                    Adv Ther  \n                    2006; \n                    23\n                    (3)\n                    : 385-94.","journal-title":"Adv. Ther."},{"key":"refR11","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ophtha.2015.09.005.","volume":"123","author":"Li T.","year":"2015","unstructured":"Li T, Lindsley K, Rouse B, et al. \n                    Comparative effectiveness of first-line medications for primary open-angle glaucoma: a systematic review and network meta-analysis. \n                    Ophthalmology  \n                    2015; \n                    123\n                    (1)\n                    : 129-40.","journal-title":"Ophthalmology"},{"key":"refR12","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.2147\/OPTH.S87613","volume":"9","author":"Maruyama Y.","year":"2015","unstructured":"Maruyama Y, Ikeda Y, Mori K, Ueno M, Yoshikawa H, Kinoshita S. \n                    Comparison between bimatoprost and latanoprost-timolol fixed combination for efficacy and safety after switching patients from latanoprost. \n                    Clin Ophthalmol  \n                    2015; \n                    9\n                    : 1429-36.","journal-title":"Clin. Ophthalmol."},{"key":"refR13","doi-asserted-by":"publisher","first-page":"e0140601","DOI":"10.1371\/journal.pone.0140601","volume":"10","author":"Oddone F.","year":"2015","unstructured":"Oddone F, Rossetti L, Tanga L, et al. \n                    Effects of topical bimatoprost 0.01% and timolol 0.5% on circadian iop, blood pressure and perfusion pressure in patients with glaucoma or ocular hypertension: A randomized, double masked, placebo-controlled clinical trial. \n                    PLoS One  \n                    2015; \n                    10\n                    (10)\n                    : e0140601.","journal-title":"PLoS One"},{"key":"refR14","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s10384-012-0139-2","volume":"56","author":"Kashiwagi K.","year":"2012","unstructured":"Kashiwagi K. \n                    Efficacy and safety of switching to travoprost\/timolol fixed-combination therapy from latanoprost monotherapy. \n                    Jpn J Ophthalmol  \n                    2012; \n                    56\n                    (4)\n                    : 339-45.","journal-title":"Jpn. J. Ophthalmol."},{"key":"refR15","first-page":"411","volume":"49","author":"Mandi\u0107 Z.","year":"2010","unstructured":"Mandi\u0107 Z, Novak-Laus K, Boji\u0107 L, et al. \n                    Safety and efficacy of monotherapy change to fixed combination (travoprost 0.004%\/timolol 0.5%) in 6 months follow up period. \n                    Acta Clin Croat  \n                    2010; \n                    49\n                    (4)\n                    : 411-9.","journal-title":"Acta Clin. Croat."},{"key":"refR16","doi-asserted-by":"publisher","first-page":"459","DOI":"10.2147\/OPTH.S10694","volume":"4","author":"Pfeiffer N.","year":"2010","unstructured":"Pfeiffer N, Scherzer ML, Maier H, et al. \n                    Safety and efficacy of changing to the travoprost\/timolol maleate fixed combination (DuoTrav) from prior mono- or adjunctive therapy. \n                    Clin Ophthalmol  \n                    2010; \n                    4\n                    : 459-66.","journal-title":"Clin. Ophthalmol."},{"key":"refR17","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1185\/030079907X178720","volume":"23","author":"Denis P.","year":"2007","unstructured":"Denis P, Lafuma A, Khoshnood B, Mimaud V, Berdeaux G. \n                    A meta-analysis of topical prostaglandin analogues intra-ocular pressure lowering in glaucoma therapy. \n                    Curr Med Res Opin  \n                    2007; \n                    23\n                    (3)\n                    : 601-8.","journal-title":"Curr. Med. Res. Opin."},{"key":"refR18","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1358\/dot.2007.43.2.1032058","volume":"43","author":"Noecker R.J.","year":"2007","unstructured":"Noecker RJ, Awadallah NS, Kahook MY. \n                    Travoprost 0.004%\/timolol 0.5% fixed combination. \n                    Drugs Today (Barc)  \n                    2007; \n                    43\n                    (2)\n                    : 77-83.","journal-title":"Drugs Today (Barc)"},{"key":"refR19","doi-asserted-by":"publisher","first-page":"703","DOI":"10.2147\/OPTH.S3997","volume":"2","author":"Ishikawa S.","year":"2008","unstructured":"Ishikawa S, Nakamura Y, Nakamura Y, et al. \n                    Efficacy and safety of combination therapy with latanoprost after a change in therapeutic regimen from timolol to brinzolamide in Japanese adult patients with primary open-angle glaucoma and ocular hypertension: open, non-randomized 12-week study. \n                    Clin Ophthalmol  \n                    2008; \n                    2\n                    (4)\n                    : 703-8.","journal-title":"Clin. Ophthalmol."},{"key":"refR20","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1159\/000225963","volume":"42","author":"Cheng J.W.","year":"2009","unstructured":"Cheng JW, Li Y, Wei RL. \n                    Systematic review of intraocular pressure-lowering effects of adjunctive medications added to latanoprost. \n                    Ophthalmic Res  \n                    2009; \n                    42\n                    (2)\n                    : 99-105.","journal-title":"Ophthalmic Res."},{"key":"refR21","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.brainres.2009.09.029","volume":"1303","author":"Zhang S.","year":"2009","unstructured":"Zhang S, Wang H, Lu Q, et al. \n                    Detection of early neuron degeneration and accompanying glial responses in the visual pathway in a rat model of acute intraocular hypertension. \n                    Brain Res  \n                    2009; \n                    1303\n                    : 131-43.","journal-title":"Brain Res."},{"key":"refR22","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1136\/bjo.2007.123737","volume":"92","author":"Hodge W.G.","year":"2008","unstructured":"Hodge WG, Lachaine J, Steffensen I, et al. \n                    The efficacy and harm of prostaglandin analogues for IOP reduction in glaucoma patients compared to dorzolamide and brimonidine: a systematic review. \n                    Br J Ophthalmol  \n                    2008; \n                    92\n                    (1)\n                    : 7-12.","journal-title":"Br. J. Ophthalmol."},{"key":"refR23","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1001\/archopht.121.11.1537","volume":"121","author":"Miyata K.","year":"2003","unstructured":"Miyata K, Amano S, Sawa M, Nishida T. \n                    A novel grading method for superficial punctate keratopathy magnitude and its correlation with corneal epithelial permeability. \n                    Arch Ophthalmol  \n                    2003; \n                    121\n                    (11)\n                    : 1537-9.","journal-title":"Arch. Ophthalmol."},{"key":"refR24","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1097\/IJG.0b013e3181666557","volume":"17","author":"Aptel F.","year":"2008","unstructured":"Aptel F, Cucherat M, Denis P. \n                    Efficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trials. \n                    J Glaucoma  \n                    2008; \n                    17\n                    (8)\n                    : 667-73.","journal-title":"J. Glaucoma"},{"key":"refR25","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1007\/s10384-012-0155-2","volume":"56","author":"Kawaguchi I.","year":"2012","unstructured":"Kawaguchi I, Higashide T, Ohkubo S, Kawaguchi C, Sugiyama K. \n                    Comparison of efficacy of four prostaglandin analogues by bilateral treatment in healthy subjects. \n                    Jpn J Ophthalmol  \n                    2012; \n                    56\n                    (4)\n                    : 346-53.","journal-title":"Jpn. J. Ophthalmol."},{"key":"refR26","doi-asserted-by":"publisher","first-page":"739","DOI":"10.2147\/OPTH.S31330","volume":"6","author":"Pfennigsdorf S.","year":"2012","unstructured":"Pfennigsdorf S, Ramez O, von Kistowski G, et al. \n                    Multicenter, prospective, open-label, observational study of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension. \n                    Clin Ophthalmol  \n                    2012; \n                    6\n                    : 739-46.","journal-title":"Clin. Ophthalmol."},{"key":"refR27","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1089\/jop.2011.0020","volume":"27","author":"Sato S.","year":"2011","unstructured":"Sato S, Hirooka K, Baba T, et al. \n                    Efficacy and safety of switching from topical latanoprost to bimatoprost in patients with normal-tension glaucoma. \n                    J Ocul Pharmacol Ther  \n                    2011; \n                    27\n                    (5)\n                    : 499-502.","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"refR28","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1089\/jop.2013.0108","volume":"29","author":"Nixon D.R.","year":"2013","unstructured":"Nixon DR. \n                    A randomized, prospective study of bimatoprost 0.01% or travoprost\/timolol in patients previously treated with latanoprost and timolol to reduce intraocular pressure. \n                    J Ocul Pharmacol Ther  \n                    2013; \n                    29\n                    (10)\n                    : 876-81.","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"refR29","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1185\/030079908X301848","volume":"24","author":"Day D.G.","year":"2008","unstructured":"Day DG, Hollander DA. \n                    Brimonidine purite 0.1% versus brinzolamide 1% as adjunctive therapy to latanoprost in patients with glaucoma or ocular hypertension. \n                    Curr Med Res Opin  \n                    2008; \n                    24\n                    (5)\n                    : 1435-42.","journal-title":"Curr. Med. Res. Opin."},{"key":"refR30","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1097\/IJG.0b013e31815072fe","volume":"17","author":"Miura K.","year":"2008","unstructured":"Miura K, Ito K, Okawa C, Sugimoto K, Matsunaga K, Uji Y. \n                    Comparison of ocular hypotensive effect and safety of brinzolamide and timolol added to latanoprost. \n                    J Glaucoma  \n                    2008; \n                    17\n                    (3)\n                    : 233-7.","journal-title":"J. Glaucoma"},{"key":"refR31","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/j.jclinepi.2008.04.012","volume":"62","author":"van der Valk R.","year":"2009","unstructured":"van der Valk R, Webers CA, Lumley T, Hendrikse F, Prins MH, Schouten JS. \n                    A network meta-analysis combined direct and indirect comparisons between glaucoma drugs to rank effectiveness in lowering intraocular pressure. \n                    J Clin Epidemiol  \n                    2009; \n                    62\n                    (12)\n                    : 1279-83.","journal-title":"J. Clin. Epidemiol."},{"key":"refR32","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/S0002-9394(03)00098-9","volume":"135","author":"Parrish R.K.","year":"2003","unstructured":"Parrish RK, Palmberg P, Sheu WP. \n                    A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. \n                    Am J Ophthalmol  \n                    2003; \n                    135\n                    (5)\n                    : 688-703.","journal-title":"Am. J. Ophthalmol."},{"key":"refR33","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1136\/bjo.2007.135111","volume":"93","author":"Honrubia F.","year":"2009","unstructured":"Honrubia F, Garc\u00eda-S\u00e1nchez J, Polo V, de la Casa JM, Soto J. \n                    Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomised clinical trials. \n                    Br J Ophthalmol  \n                    2009; \n                    93\n                    (3)\n                    : 316-21.","journal-title":"Br. J. Ophthalmol."},{"key":"refR34","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1177\/112067210901900312","volume":"19","author":"Kurtz S.","year":"2009","unstructured":"Kurtz S, Mann O. \n                    Incidence of hyperemia associated with bimatoprost treatment in na\u00efve subjects and in subjects previously treated with latanoprost. \n                    Eur J Ophthalmol  \n                    2009; \n                    19\n                    (3)\n                    : 400-3.","journal-title":"Eur. J. Ophthalmol."},{"key":"refR35","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.2147\/OPTH.S36628","volume":"6","author":"Tsumura T.","year":"2012","unstructured":"Tsumura T, Yoshikawa K, Suzumura H, et al. \n                    Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events. \n                    Clin Ophthalmol  \n                    2012; \n                    6\n                    : 1547-52.","journal-title":"Clin. Ophthalmol."},{"key":"refR36","doi-asserted-by":"publisher","first-page":"S105","DOI":"10.1016\/S0039-6257(02)00327-2","volume":"47","author":"Eisenberg D.L.","year":"2002","unstructured":"Eisenberg DL, Toris CB, Camras CB. \n                    Bimatoprost and travoprost: a review of recent studies of two new glaucoma drugs. \n                    Surv Ophthalmol  \n                    2002; \n                    47\n                    (Suppl 1)\n                    : S105-15.","journal-title":"Surv. Ophthalmol."},{"key":"refR37","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s00417-004-0866-2","volume":"242","author":"Manni G.","year":"2004","unstructured":"Manni G, Centofanti M, Parravano M, Oddone F, Bucci MG. \n                    A 6-month randomized clinical trial of bimatoprost 0.03% versus the association of timolol 0.5% and latanoprost 0.005% in glaucomatous patients. \n                    Graefes Arch Clin Exp Ophthalmol  \n                    2004; \n                    242\n                    (9)\n                    : 767-70.","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"refR38","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1007\/s10384-011-0075-6","volume":"55","author":"Aihara M.","year":"2011","unstructured":"Aihara M, Shirato S, Sakata R. \n                    Incidence of deepening of the upper eyelid sulcus after switching from latanoprost to bimatoprost. \n                    Jpn J Ophthalmol  \n                    2011; \n                    55\n                    (6)\n                    : 600-4.","journal-title":"Jpn. J. Ophthalmol."}],"container-title":["The Open Ophthalmology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/openophthalmologyjournal.com\/contents\/volumes\/V10\/TOOPHTJ-10-94\/TOOPHTJ-10-94.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/openophthalmologyjournal.com\/contents\/volumes\/V10\/TOOPHTJ-10-94\/TOOPHTJ-10-94.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/openophthalmologyjournal.com\/contents\/volumes\/V10\/TOOPHTJ-10-94\/TOOPHTJ-10-94.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,15]],"date-time":"2019-04-15T06:25:37Z","timestamp":1555309537000},"score":1,"resource":{"primary":{"URL":"https:\/\/openophthalmologyjournal.com\/VOLUME\/10\/PAGE\/94\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,7]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,3,7]]}},"alternative-id":["TOOPHTJ-10-94"],"URL":"https:\/\/doi.org\/10.2174\/1874364101610010094","relation":{},"ISSN":["1874-3641"],"issn-type":[{"value":"1874-3641","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3,7]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2015-11-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-12-17","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-12-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-3-7","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}